<DOC>
	<DOCNO>NCT00574652</DOCNO>
	<brief_summary>A systemic Vasculitis find 5 10 % HCV infect patient mixed cryoglobulinemia ( MC ) . It mainly involve skin , peripheral nerve kidney may life threaten . Twenty 30 % HCV-MC Vasculitis patient resistant conventional therapy ( i.e . antiviral therapy and/or immunosuppressor ) still active disease . Thus , new therapeutic approach necessary patient . We recently describe regulatory T cell ( Treg ) deficiency HCV-related Vasculitis patient . Immunomodulatory effect interleukin-2 ( IL-2 ) well establish , notably preferential expansion Treg able suppress inflammatory response mediate CD4+ CD8+ T cell .</brief_summary>
	<brief_title>Evaluation Clinical Efficacy Immunologic Response After IL-2 Therapy HCV-related Vasculitis Patients</brief_title>
	<detailed_description>A systemic Vasculitis find 5 10 % HCV infect patient mixed cryoglobulinemia ( MC ) . It mainly involve skin , peripheral nerve kidney may life threaten ( 15 % death ) . Twenty 30 % HCV-MC Vasculitis patient resistant conventional therapy ( i.e . antiviral therapy and/or immunosuppressor ) still active disease . An antiviral therapy Peg-interf√©ron generally prescribe control Vasculitis lesion slow hepatic fibrosis progression . Thus , new therapeutic approach necessary patient . We recently describe CD4+ CD25+ regulatory T cell ( Treg ) deficiency HCV-related Vasculitis patient . Immunomodulatory effect interleukin-2 ( IL-2 ) well establish , notably preferential expansion Treg able suppress inflammatory response mediate CD4+ CD8+ T cell . Objective : To evaluate cellular immune response IL-2 therapy HCV-MC Vasculitis patient , resistant conventional therapy . Methods : This open prospective phase I/II trial . Four cycle subcutaneous IL-2 therapy ( 3 million IU/day day 1 5 every 21 day carry W1 , W3 , W6 , W9 ) . The first cure carry half-dose IL-2 ( 1.5 million IU/day ) hospital . If tolerance satisfactory , later cure do ambulatory . All patient follow IL-2 therapy ( S11 S37 ) . End point : 1 . Clinical tolerance : Absence Vasculitis flare IL-2 therapy . 2 . Immunologic follow-up Treg HCV cellular immune response , IL-2 therapy . 3 . Clinical efficacy : follow-up clinical manifestation HCV-MC Vasculitis IL-2 therapy . Schedule : Duration patient ' inclusion period estimate 18 month . Duration therapy follow-up estimate 9 month . Analysis data last 7 month . Overall duration : 34 month</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Cryoglobulinemia</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>1 . HCV+ patient cryoglobulinemia Vasculitis 2. resistant conventional therapy ( i.e . antiviral therapy and/or immunosuppressor ) . 3 . Vasculitis define accord international criterion : chronic HCV infection ( HCV RNA+ ) , 4. serum cryoglobulin superior equal 0.05g/l least two determination , 5. presence triad purpuraarthralgiaasthenia and/or biopsy prove Vasculitis ( kidney , nerve skin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>HCV+</keyword>
	<keyword>cryoglobulinemia</keyword>
	<keyword>Vasculitis</keyword>
	<keyword>IL-2 treatment</keyword>
	<keyword>safety efficacy</keyword>
</DOC>